In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Published Date: 03 Jun 2024

According to experts, the benefit-risk profile may alter the way CML is treated.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

2.

Mezigdomide Combinations Show Promise in Multiple Myeloma

3.

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

4.

Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.

5.

Oleanolic acid from grapes may increase chemotherapy effectiveness


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot